Sangamo Therapeutics(SGMO) - 2025 Q3 - Quarterly Results

Held productive interaction with Medicines and Healthcare products Regulatory Agency (MHRA) to discuss prion disease study ahead of anticipated Clinical Trial Application (CTA) submission. RICHMOND, California, November 6, 2025 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and third quarter 2025 financial results. "We continued to advance our clinical and pre-clinical pipeline this quarter and are excited to now be recruiting and enrolling ...